[go: up one dir, main page]

WO2009075890A3 - Method for synthesis of triazole compounds that modulate hsp90 activity - Google Patents

Method for synthesis of triazole compounds that modulate hsp90 activity Download PDF

Info

Publication number
WO2009075890A3
WO2009075890A3 PCT/US2008/013671 US2008013671W WO2009075890A3 WO 2009075890 A3 WO2009075890 A3 WO 2009075890A3 US 2008013671 W US2008013671 W US 2008013671W WO 2009075890 A3 WO2009075890 A3 WO 2009075890A3
Authority
WO
WIPO (PCT)
Prior art keywords
synthesis
triazole compounds
hsp90 activity
modulate hsp90
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/013671
Other languages
French (fr)
Other versions
WO2009075890A8 (en
WO2009075890A2 (en
Inventor
Dinesh U Chimmanamada
Shije Zhang
Chi-Wan Lee
Teresa Przewloka
Weiwen Ying
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of WO2009075890A2 publication Critical patent/WO2009075890A2/en
Publication of WO2009075890A3 publication Critical patent/WO2009075890A3/en
Publication of WO2009075890A8 publication Critical patent/WO2009075890A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/56—Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel method of synthesis of compounds which inhibit the activity of Hsp90. In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) cyclization of a compound of formula (II): in a base/solvent, thereby producing a compound of formula (IA). The definition of the substituents and the conditions of the reactions are provided herein.
PCT/US2008/013671 2007-12-12 2008-12-12 Method for synthesis of triazole compounds that modulate hsp90 activity Ceased WO2009075890A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US739107P 2007-12-12 2007-12-12
US61/007,391 2007-12-12

Publications (3)

Publication Number Publication Date
WO2009075890A2 WO2009075890A2 (en) 2009-06-18
WO2009075890A3 true WO2009075890A3 (en) 2009-08-13
WO2009075890A8 WO2009075890A8 (en) 2009-10-01

Family

ID=40451133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/013671 Ceased WO2009075890A2 (en) 2007-12-12 2008-12-12 Method for synthesis of triazole compounds that modulate hsp90 activity

Country Status (1)

Country Link
WO (1) WO2009075890A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949467B1 (en) 2009-09-03 2011-11-25 Sanofi Aventis NOVEL 5,6,7,8-TETRAHYDROINDOLIZINE DERIVATIVES INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME AND USE THEREOF
US20130225870A1 (en) * 2010-08-25 2013-08-29 Synta Pharmaceuticals Corp. Method of synthesizing substituted 2-alkyl phenols
EP3300500B9 (en) 2015-05-20 2021-01-13 Amgen Inc. Triazole agonists of the apj receptor
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139967A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007139968A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139967A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007139968A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity

Also Published As

Publication number Publication date
WO2009075890A8 (en) 2009-10-01
WO2009075890A2 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
WO2009075890A3 (en) Method for synthesis of triazole compounds that modulate hsp90 activity
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2008005368A3 (en) Piperazines as p2x7 antagonists
UA94833C2 (en) Substituted bicyclolactams
WO2009020140A1 (en) Adamantylurea derivative
WO2006135640A3 (en) Process for the synthesis of organic compounds
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2009121033A3 (en) Substituted nitrogen heterocycles and synthesis and uses thereof
EP2039693A3 (en) Novel synthesis of irbesartan
WO2007000339A8 (en) Bicyclic derivatives as p38 kinase inhibitors
WO2005087700A3 (en) Bisphenyl compounds useful as vitamin d3 receptor agonists
MY144657A (en) Crystalline polymorphs of a cxc-chemokine receptor ligand.
WO2007045420A3 (en) 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors
TW200638930A (en) Acetylene derivatives
WO2004002990A3 (en) Synthesis of purine derivatives
WO2005085236A3 (en) Caspase inhibitors and uses thereof
WO2007106564A3 (en) Synthesis of thrombopoietin activity modulating compounds
WO2009039362A3 (en) Chiral synthesis of diazepinoquinolines
NO20071817L (en) Process for Preparing Enantiomeric Imidazole Compounds
WO2007006533A3 (en) Indolylmaleimide derivatives
MY152557A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
WO2011161255A3 (en) Processes for the resolution of nitrogen substituted (s) - 5 -alkoxy- 2 -aminotetralin derivatives
TW200730480A (en) Organic compounds
TW200726752A (en) Process for the production of intermediates for the preparation of tricyclic benzimidazoles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08859448

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08859448

Country of ref document: EP

Kind code of ref document: A2